CFB rs2072633: Macular Health & Anti-VEGF Therapy
The rs2072633 variant is a single-nucleotide polymorphism located in the complement factor B (CFB) gene. It has been investigated for its association with age-related macular degeneration (AMD) risk, notably showing protective trends against neovascular AMD and influencing therapeutic response to anti-VEGF injections in select cohorts. While moderate evidence supports its role in complement regulation, associations can vary significantly across diverse populations.
What each genotype means
Typical complement factor B profile
This genotype represents the homozygous state for the minor allele. Research suggests that individuals with this variant may show different responses to anti-VEGF therapy for neovascular AMD compared to those with the G allele, though findings across studies are mixed and sometimes contradictory. Please discuss any treatment plans or medication responses with your ophthalmologist or healthcare provider.
The A allele is less common than the G allele, making this genotype relatively infrequent in most global populations.
Mixed complement factor B profile
This heterozygous genotype contains one copy of each allele. Some studies have investigated whether this variant influences the effectiveness of anti-VEGF treatments for age-related macular degeneration, but results remain inconsistent across different research cohorts. You should consult with your clinician regarding your specific clinical history and treatment options.
This is a common genotype found in a significant portion of the population, consistent with the reported minor allele frequency of 0.20-0.35.
Common complement factor B profile
This genotype is the homozygous state for the major allele. While some research has associated the G allele with specific responses to anti-VEGF therapy in patients with neovascular AMD, other studies have found no significant association with overall disease risk. Always discuss your clinical management and medication response with your eye care specialist.
This is the most prevalent genotype for this variant across most global populations.
What Is rs2072633 and Where Is It Located?
The single-nucleotide polymorphism rs2072633 is a naturally occurring genetic variant found within the human complement factor B (CFB) gene locus on chromosome 6. In genetic datasets such as dbSNP, this polymorphism is primarily documented as an exchange between guanine (G) and adenine (A) alleles. It sits in a dense cluster of immune-related genes, closely neighboring complement component 2 (C2) and components of the major histocompatibility complex (MHC). Because of its physical location in the genome, rs2072633 is often evaluated as part of larger haplotype blocks that influence the alternative pathway of the complement cascade. Rather than acting as a rare pathogenic mutation that disables gene function, rs2072633 represents a common sequence variation that slightly shifts baseline regulatory signals or interacts with surrounding genetic markers. Researchers study it to understand how subtle differences in complement pathway architecture contribute to complex, multifactorial conditions affecting ocular tissues.
The Biological Role of Complement Factor B (CFB)
The CFB gene provides instructions for producing complement factor B, an essential component of the body's innate immune system. As detailed in resources like UniProt and NCBI Gene, complement factor B functions as a serine protease that participates in the alternative pathway of the complement system. When activated by factor D, factor B is cleaved into fragments that help form the C3 and C5 convertases. These enzymes drive a cascade responsible for targeting pathogens, clearing damaged host debris, and maintaining inflammatory homeostasis. In healthy tissue, this inflammatory response is tightly modulated by regulatory proteins such as complement factor H. However, in sensitive tissues like the retina and retinal pigment epithelium, dysregulation of complement activation can lead to chronic low-grade inflammation, accumulation of subretinal deposits (drusen), and tissue damage. Variations in the CFB gene modulate the intensity of this pathway, shifting the balance between cellular defense and local tissue destruction.
Research Findings: AMD Risk and Anti-VEGF Treatment Response
Genome-wide association studies and candidate-gene investigations have extensively explored the C2/CFB locus for its connection to age-related macular degeneration. Specific studies have correlated the minor allele of rs2072633 with a reduced risk of progressing to advanced neovascular (wet) AMD, as well as favorable anatomical and visual outcomes following anti-VEGF (vascular endothelial growth factor) eye therapy. Anti-VEGF agents are standard-of-care biologic injections used to halt aberrant choroidal neovascularization. While several cohort studies highlight favorable associations, overall findings across the broader literature remain nuanced. Meta-analyses in the public research record show that statistical significance can vary substantially between ethnic cohorts, with some pooled analyses demonstrating negligible independent effects after controlling for linkage disequilibrium with other complement genes like CFH and C2. Consequently, evidence for rs2072633 is classified as moderate, representing a statistical modifier rather than a standalone clinical determinant.
Population Frequency and Ancestral Distribution
The rs2072633 polymorphism is widely distributed across global human populations, exhibiting a minor allele frequency typically ranging between 0.20 and 0.35 in major reference panels like gnomAD and 1000 Genomes. While both the major G allele and the minor A allele appear across European, Asian, African, and American ancestral groups, their exact proportions shift regionally. In certain East Asian cohorts, the frequency of the protective minor allele has been noted to diverge compared to European cohorts, which may explain why some studies report varying effect sizes for macular degeneration across different geographic groups. Because genetic background shapes how neighboring complement genes interact, the biological effect associated with carrying one or two copies of the minor allele cannot be evaluated in isolation from broader ancestral genetics.
Interpreting Your Results Responsibly
Identifying your rs2072633 genotype can offer insight into your inherited complement biology, but it is essential to understand what this information cannot do. An individual genetic variant does not diagnose age-related macular degeneration, nor does it guarantee protection from vision loss or predict absolute response to medical therapies. Neovascular AMD is a complex condition driven by a combination of advancing age, tobacco use, diet, cardiovascular health, and polygenic risk factors across dozens of genomic loci. Furthermore, pharmacogenomic associations regarding anti-VEGF therapy are observational and intended for scientific research. Patients should never initiate, discontinue, or alter any prescribed treatment regimen based on personal genetic test results. All medical decisions and eye health evaluations should be conducted under the guidance of a qualified ophthalmologist, physician, or clinical geneticist.
How common is this variant?
The minor allele at rs2072633 occurs at an estimated frequency of 0.20 to 0.35 across major global populations, with heterozygous and homozygous minor genotypes common in European, Asian, and African reference cohorts.
Frequently asked questions
What does the CFB rs2072633 variant do in the body?
The rs2072633 variant sits within the CFB gene, which codes for complement factor B. This protein helps regulate the alternative complement cascade, an essential arm of the immune system that controls inflammation and cell clearance in tissues such as the retina.
Does having rs2072633 mean I will not develop macular degeneration?
No. While the minor allele has been statistically correlated with lower risks of neovascular (wet) AMD, it provides only relative protection rather than total immunity. Factors like age, smoking, cardiovascular health, and other complement genes play massive roles in overall disease susceptibility.
Can this genetic test determine which eye injection I should receive?
No. Although researchers study whether rs2072633 influences the effectiveness of anti-VEGF drugs like bevacizumab or ranibizumab, these associations are not approved for clinical decision-making. Treatment choices must always be determined by your ophthalmologist based on clinical examinations.
How common is the rs2072633 variant across different ancestries?
The minor allele is common worldwide, appearing at an overall frequency between 20% and 35% in large global genomic databases. Frequencies are relatively stable across European, Asian, and African populations, though exact genotype distributions can vary slightly by region.
Sources & further reading
Educational information only, last refreshed 9/8/2026. Not medical advice — these associations describe population statistics, not individual predictions.
Curious what your genotype is for rs2072633?
Upload a raw DNA file from 23andMe, AncestryDNA, MyHeritage, or FamilyTreeDNA and see this variant — plus thousands more — interpreted in your full report.
Get my report — $29